Abstract
AbstractRapid, inexpensive, robust diagnostics are essential to control the spread of infectious diseases. Current state of the art diagnostics are highly sensitive and specific, but slow, and require expensive equipment. Here we report the development of a molecular diagnostic test for SARS-CoV-2 based on an enhanced recombinase polymerase amplification (eRPA) reaction. eRPA has a detection limit on patient samples down to 5 viral copies, requires minimal instrumentation, and is highly scalable and inexpensive. eRPA does not cross-react with other common coronaviruses, does not require RNA purification, and takes ~45 min from sample collection to results. eRPA represents a first step toward at-home SARS-CoV-2 detection and can be adapted to future viruses within days of genomic sequence availability.
Funder
United States Department of Defense | Defense Advanced Research Projects Agency
Publisher
Springer Science and Business Media LLC
Subject
General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry
Reference38 articles.
1. Dong, E., Du, H. & Gardner, L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect. Dis. 20, 533–534 (2020).
2. Park, A. Dr. Anthony Fauci “not overly confident” with U.S. COVID-19 testing capabilities. time.comanthony-fauci-covid–testing-capabilities. Accessed 24 May 2020.
3. Temple, J. Why contact tracing may be a mess in America. Accessed 24 May 2020.
4. Vogels, C. B. F. et al. SalivaDirect: A simplified and flexible platform to enhance SARS-CoV-2 testing capacity. medRxiv. https://doi.org/10.1101/2020.08.03.20167791 (2020).
5. Srivatsan, S. et al. Preliminary support for a ‘dry swab, extraction free’ protocol for SARS-CoV-2 testing via RT-qPCR. bioRxiv https://doi.org/10.1101/2020.04.22.056283 (2020).
Cited by
127 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献